<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929044</url>
  </required_header>
  <id_info>
    <org_study_id>202.848</org_study_id>
    <nct_id>NCT01929044</nct_id>
  </id_info>
  <brief_title>Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain</brief_title>
  <official_title>A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in
      comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PID From Pre-dose Baseline at 20 Minutes After First Injection.</measure>
    <time_frame>Baseline and 20 minutes after the first injection</time_frame>
    <description>Pain intensity difference (PID) from pre-dose baseline at 20 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PID From Pre-dose Baseline at 10 Minutes After First Injection.</measure>
    <time_frame>Baseline and 10 minutes after the first injection</time_frame>
    <description>Pain intensity difference (PID) from pre-dose baseline at 10 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PID From Pre-dose Baseline at 30 Minutes After First Injection.</measure>
    <time_frame>Baseline and 30 minutes after the first injection</time_frame>
    <description>Pain intensity difference (PID) from pre-dose baseline at 30 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PID From Pre-dose Baseline at 60 Minutes After First Injection.</measure>
    <time_frame>Baseline and 60 minutes after the first injection</time_frame>
    <description>Pain intensity difference (PID) from pre-dose baseline at 60 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PID From Pre-dose Baseline at 120 Minutes After First Injection.</measure>
    <time_frame>Baseline and 120 minutes after the first injection</time_frame>
    <description>Pain intensity difference (PID) from pre-dose baseline at 120 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Efficacy by the Patient at 120 Minutes After the First Injection</measure>
    <time_frame>120 minutes after the first injection</time_frame>
    <description>Global assessment of efficacy by the patient. The patient was to assess the efficacy at 120 min after the first injection using a 4-point rating scale by answering the question: &quot;How would you rate the effect of the study medication for relieving your acute gastric or intestinal spasm-like pain?&quot; (0 = poor; 1 = fair; 2 = good; 3 = very good).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Need the Second Injection</measure>
    <time_frame>20 minutes after the first injection.</time_frame>
    <description>Proportion of patients who need the second injection at 20 minutes after the first injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Intestinal Diseases</condition>
  <arm_group>
    <arm_group_label>Buscopan® (hyoscine butylbromide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>654-II(anisodamine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>654-II (anisodamine)</intervention_name>
    <description>10mg injection</description>
    <arm_group_label>654-II(anisodamine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buscopan® (hyoscine butylbromide)</intervention_name>
    <description>20mg injection</description>
    <arm_group_label>Buscopan® (hyoscine butylbromide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients must sign and date an Informed Consent consistent with International
             Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local
             regulation prior to participation in the trial.

          2. Patients must agree to cooperate with all trial evaluations and perform all required
             tasks.

          3. Patients with acute gastric or intestinal spasm-like pain (without severe vomiting and
             surgical acute abdomen).

          4. Male or female patients aged 18 to 70 years.

          5. The pain intensity upon screening is at least point 6 on a 0-10 numerical rating scale
             (NRS).

        Exclusion criteria:

          1. Patients with the following concomitant disease is not eligible for enrollment:

               -  Painful gastric or intestinal spasm of organic origin such as Crohn's disease,
                  ulcerative colitis, lactose intolerance, gastrointestinal perforation, suspected
                  gastrointestinal perforation or peritoneal effusion.

               -  Pain related with malignancy.

               -  Patients with other severe pain states of organic origin.

               -  Mechanical stenosis of the gastrointestinal tract ,megacolin.

               -  Urinary retention associated with mechanical stenosis of urinary tract.

               -  Narrow-angled glaucoma.

               -  Tachyarrhythmia.

               -  Myasthenia gravis.

               -  Meulengracht-Gilbert syndrome.

               -  Known depression or known mental illness, anxiety disturbance.

          2. Patients taking the following concomitant medication within 7 half-life of concomitant
             medication (the duration from taking concomitant medication to attending the trial is
             less than 7 half-life) are not eligible for enrollment:

               -  Analgesics,

               -  Spasmolytics,

               -  Anticholinergics

               -  Affecting gastrointestinal motility, such as propantheline, metoclopramide,
                  cisapride, loperamide, diphenoxylate, opioid analgesics, antacids and other ulcer
                  treatment

               -  Regular administration of laxatives

               -  Narcotics

               -  Antidepressant treatment or treatment with psychoactive drugs

          3. Pregnancy and/or lactation or planned pregnancy;

          4. Known hypersensitivity to N-butylscopolammonium bromide

          5. Alcohol, or drug abuse.

          6. Simultaneous participating in another clinical trial, or discontinuing from another
             clinical trial before randomization (administration of study medication); moreover, in
             the case of screening failure or premature discontinuing from the trial, repeated
             enrollment is forbidden.

          7. Unwilling to or unable to complete the entire trial procedure according to the
             protocol.

          8. In investigator's opinion, the patient is not proper for the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>202.848.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chenzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huanggang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202.848.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>February 10, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2016</results_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Anisodamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>299 patients were entered and 295 were treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Buscopan® (Hyoscine Butylbromide)</title>
          <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
        </group>
        <group group_id="P2">
          <title>654-II (Anisodamine)</title>
          <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): All randomised patients who received at least one dose of study medication constituted the treated set. One patient was randomized to 654-II but incorrectly treated with Buscopan® so in the disposition table and efficacy analysis, number of patients are 152 and 143 while for demographic and AE analysis, they are 153 and 142.</population>
      <group_list>
        <group group_id="B1">
          <title>Buscopan® (Hyoscine Butylbromide)</title>
          <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
        </group>
        <group group_id="B2">
          <title>654-II (Anisodamine)</title>
          <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="14.2"/>
                    <measurement group_id="B2" value="40.7" spread="14.8"/>
                    <measurement group_id="B3" value="41.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PID From Pre-dose Baseline at 20 Minutes After First Injection.</title>
        <description>Pain intensity difference (PID) from pre-dose baseline at 20 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
        <time_frame>Baseline and 20 minutes after the first injection</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS: all patients who provided any data for the primary efficacy endpoint constituted the full analysis set.), who revealed no important protocol violations that would impact the analysis of primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>PID From Pre-dose Baseline at 20 Minutes After First Injection.</title>
          <description>Pain intensity difference (PID) from pre-dose baseline at 20 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS: all patients who provided any data for the primary efficacy endpoint constituted the full analysis set.), who revealed no important protocol violations that would impact the analysis of primary endpoint</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.09" spread="0.17"/>
                    <measurement group_id="O2" value="-3.66" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Restricted maximum likelihood (REML) -repeated measures approach</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>One−sided test relative to the non−inferiority margin of 1</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation is used to estimate the denominator degrees of freedom. An unstructured covariance matrix is used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>REML-based repeated measures approach includes baseline pain intensity as continuous covariate, treatment, centre, time and treatment-time interaction as fixed effects. The difference was calculated as Buscopan minus 654-II.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0743</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation is used to estimate the denominator degrees of freedom. An unstructured covariance matrix is used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>REML-based repeated measures approach includes baseline pain intensity as continuous covariate, treatment, centre, time and treatment-time interaction as fixed effects. The difference was calculated as Buscopan minus 654-II.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PID From Pre-dose Baseline at 10 Minutes After First Injection.</title>
        <description>Pain intensity difference (PID) from pre-dose baseline at 10 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
        <time_frame>Baseline and 10 minutes after the first injection</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>PID From Pre-dose Baseline at 10 Minutes After First Injection.</title>
          <description>Pain intensity difference (PID) from pre-dose baseline at 10 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="0.14"/>
                    <measurement group_id="O2" value="-2.33" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1210</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation is used to estimate the denominator degrees of freedom. An unstructured covariance matrix is used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>REML-based repeated measures approach includes baseline pain intensity as continuous covariate, treatment, centre, time and treatment-time interaction as fixed effects. The difference was calculated as Buscopan minus 654-II.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PID From Pre-dose Baseline at 30 Minutes After First Injection.</title>
        <description>Pain intensity difference (PID) from pre-dose baseline at 30 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
        <time_frame>Baseline and 30 minutes after the first injection</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>PID From Pre-dose Baseline at 30 Minutes After First Injection.</title>
          <description>Pain intensity difference (PID) from pre-dose baseline at 30 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.14" spread="0.15"/>
                    <measurement group_id="O2" value="-4.74" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0658</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation is used to estimate the denominator degrees of freedom. An unstructured covariance matrix is used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>REML-based repeated measures approach includes baseline pain intensity as continuous covariate, treatment, centre, time and treatment-time interaction as fixed effects. The difference was calculated as Buscopan minus 654-II.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PID From Pre-dose Baseline at 60 Minutes After First Injection.</title>
        <description>Pain intensity difference (PID) from pre-dose baseline at 60 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
        <time_frame>Baseline and 60 minutes after the first injection</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>PID From Pre-dose Baseline at 60 Minutes After First Injection.</title>
          <description>Pain intensity difference (PID) from pre-dose baseline at 60 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="0.14"/>
                    <measurement group_id="O2" value="-5.51" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0220</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation is used to estimate the denominator degrees of freedom. An unstructured covariance matrix is used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>REML-based repeated measures approach includes baseline pain intensity as continuous covariate, treatment, centre, time and treatment-time interaction as fixed effects. The difference was calculated as Buscopan minus 654-II.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PID From Pre-dose Baseline at 120 Minutes After First Injection.</title>
        <description>Pain intensity difference (PID) from pre-dose baseline at 120 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
        <time_frame>Baseline and 120 minutes after the first injection</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>PID From Pre-dose Baseline at 120 Minutes After First Injection.</title>
          <description>Pain intensity difference (PID) from pre-dose baseline at 120 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = ‘no pain’ to 10 = ‘worst pain possible’.</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.46" spread="0.13"/>
                    <measurement group_id="O2" value="-6.01" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0149</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation is used to estimate the denominator degrees of freedom. An unstructured covariance matrix is used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
            <estimate_desc>REML-based repeated measures approach includes baseline pain intensity as continuous covariate, treatment, centre, time and treatment-time interaction as fixed effects. The difference was calculated as Buscopan minus 654-II.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Efficacy by the Patient at 120 Minutes After the First Injection</title>
        <description>Global assessment of efficacy by the patient. The patient was to assess the efficacy at 120 min after the first injection using a 4-point rating scale by answering the question: “How would you rate the effect of the study medication for relieving your acute gastric or intestinal spasm-like pain?” (0 = poor; 1 = fair; 2 = good; 3 = very good).</description>
        <time_frame>120 minutes after the first injection</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Efficacy by the Patient at 120 Minutes After the First Injection</title>
          <description>Global assessment of efficacy by the patient. The patient was to assess the efficacy at 120 min after the first injection using a 4-point rating scale by answering the question: “How would you rate the effect of the study medication for relieving your acute gastric or intestinal spasm-like pain?” (0 = poor; 1 = fair; 2 = good; 3 = very good).</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>van Elteren test</method>
            <method_desc>The van Elteren test stratifying for centre (Cochran-Mantel-Haenszel test using modified ridit scores) was performed.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Need the Second Injection</title>
        <description>Proportion of patients who need the second injection at 20 minutes after the first injection.</description>
        <time_frame>20 minutes after the first injection.</time_frame>
        <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Buscopan® (Hyoscine Butylbromide)</title>
            <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
          <group group_id="O2">
            <title>654-II (Anisodamine)</title>
            <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Need the Second Injection</title>
          <description>Proportion of patients who need the second injection at 20 minutes after the first injection.</description>
          <population>Per-Protocol Set (PPS): All patients in full analysis set (FAS), who revealed no important protocol violations that would impact the analysis of primary endpoint.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="17.81" upper_limit="32.58"/>
                    <measurement group_id="O2" value="33.9" lower_limit="25.70" upper_limit="42.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0992</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model was used to evaluate the response with treatment as fixed effect and baseline pain intensity as continuous covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Exact 95% confidence interval obtained by Clopper and Pearson approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first study drug application until 2 days (inclusive) after the last study drug application</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buscopan® (Hyoscine Butylbromide)</title>
          <description>Single intramuscular injection of 20 mg Buscopan® solution (if needed, second injection with 20 mg was to be made at 20 min after the first one) was administered to the patients</description>
        </group>
        <group group_id="E2">
          <title>654-II (Anisodamine)</title>
          <description>Single intramuscular injection of 10 mg Anisodamine solution (if needed, second injection with 10 mg was to be made at 20 min after the first one) was administered to the patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

